Markets:

Overview

News

Currencies

International

Treasuries

Adaptimmune Therapeutics plc - American Depositary Shares (NQ:ADAP)

0.0549 UNCHANGED

Last Price Updated: 4:00 PM EDT, Oct 27, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Adaptimmune Therapeutics plc - American Depositary Shares

< Previous 1 2 3 Next >

Adaptimmune to Report Q4 and Full Year 2023 Financial and Business Updates on Wednesday, March 6, 2024

February 21, 2024

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - February 21, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining...

Via Newsfile

Adaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review

January 31, 2024

If approved, afami-cel will be the first engineered T-cell therapy for solid tumors and the first effective treatment option for...

Via Newsfile

Adaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million - Presentation at JP Morgan Healthcare Conference

January 04, 2024

Sarcoma franchise of afami-cel and lete-cel leverages same development and commercial footprint with US peak year sales projected to be...

Via Newsfile

Adaptimmune Completes Submission of Rolling Biologics License Application (BLA) to U.S. FDA for Afami-cel for the Treatment of Advanced Synovial Sarcoma

December 06, 2023

First BLA for an engineered T-cell therapy for solid tumors submitted to U.S. Food and Drug AdministrationAfami-cel data demonstrate better...

Via Newsfile

Adaptimmune Receives Transfer of IND for Lete-cel Program

November 29, 2023

Interim analysis of pivotal IGNYTE-ESO trial demonstrates 40% response rate in people with synovial sarcoma or myxoid/ round cell liposarcoma...

Via Newsfile

Adaptimmune Reports Third Quarter Financial Results and Business Update

November 08, 2023

Afami-cel: overall survival for people with synovial sarcoma who received afami-cel is superior to historic controls (CTOS 2023); BLA submission...

Via Newsfile

Adaptimmune Selects ADP-600 as Clinical Candidate for Best-in Class PRAME Strategy

November 08, 2023

Candidate is 10x more sensitive to target peptide than competitor candidatesEntry into the clinic in 2024Selection of approaches from next-gen...

Via Newsfile

Adaptimmune Reports Better Outcomes for People with Synovial Sarcoma who Received Afami-cel Compared to Historical Control

October 31, 2023

~39% of patients who received afami-cel in the pivotal SPEARHEAD-1 trial had clinical responses with a median duration of response...

Via Newsfile

Adaptimmune Reports Positive Data with Lete-cel[1] from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS

October 31, 2023

40% (18/45) of people with synovial sarcoma or MRCLS and who have received ≥ 2 prior lines of therapy had...

Via Newsfile

Adaptimmune to Report Q3 2023 Financial and Business Updates on Wednesday, November 8, 2023

October 25, 2023

Philadelphia, Pennsylvania and Oxfordshire, United Kingdom--(Newsfile Corp. - October 25, 2023) - Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in...

Via Newsfile

Next-Generation TCR T-cell Therapy (ADP-A2M4CD8) Demonstrates Strong Efficacy in a Broad Range of Solid Tumors; Adaptimmune Presents Data Update from its SURPASS trial at ESMO

October 23, 2023

35% response rate in the ADP-A2M4CD8 monotherapy cohort with ~5 months median duration of response in heavily pre-treated patients across...

Via Newsfile

Dr. Karen Chagin Joins Adaptimmune as Senior Vice President of Early-Stage Development

September 11, 2023

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - September 11, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, today announces...

Via Newsfile

Adaptimmune Reports Second Quarter Financial Results and Business Update

August 09, 2023

Substantial progress on the afami-cel BLA including FDA agreement on plan for confirmatory evidence and favorable feedback on commercial T-cell...

Via Newsfile

Adaptimmune to Report Q2 2023 Financial and Business Updates on Wednesday, August 9, 2023

August 03, 2023

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - August 3, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader...

Via Newsfile

Adaptimmune Announces Completion of Strategic Combination with TCR2 Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company

June 01, 2023

First marketed engineered T-cell therapy for a solid tumor; BLA for afami-cel on track to complete submission in mid-2023Compelling clinical...

Via Newsfile

Adaptimmune Announces 70% of People with Advanced Synovial Sarcoma Who Respond to Afami-cel are Alive Two Years Post-Treatment; Data from Cohort 1 of SPEARHEAD-1 to be Presented at ASCO

May 25, 2023

Approximately 39% of patients had clinical responses after a single dose of afami-cel in Cohort 1 of the pivotal SPEARHEAD-1...

Via Newsfile

Adaptimmune Reports First Quarter Financial Results and Business Update

May 12, 2023

Completed submission of the clinical module (Part 2) of the afami-cel BLA; afami-cel is targeted to be the first marketed...

Via Newsfile

Adaptimmune to Report Q1 2023 Financial and Business Updates on Friday, May 12, 2023

April 28, 2023

Philadelphia, Pennsylvania and Oxfordshire, United Kingdom--(Newsfile Corp. - April 28, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell...

Via Newsfile

Adaptimmune and GSK Have Agreed Terms for Transfer of PRAME and NY-ESO Target Programs back to Adaptimmune

April 11, 2023

- Adaptimmune plans to be IND-ready in 2023 with a PRAME targeted TCR T-cell therapy -- Adaptimmune and GSK will...

Via Newsfile

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Diffusion Pharmaceuticals Inc. (Nasdaq- DFFN), U.S. Xpress Enterprises, Inc. (NYSE – USX), TCR² Therapeutics Inc. (Nasdaq – TCRR), Costar Technologies, Inc. (OTC –

March 30, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

TCR2 Therapeutics (NASDAQ: TCRR) and Adaptimmune Therapeutics (NASDAQ: ADAP) Announce Strategic Merger to Leverage Technologies and Create a New Major Cell Therapy Company

March 06, 2023

TCR2 Therapeutics, Inc. (NASDAQ: TCRR) operates as a clinical-stage immunotherapy company, which is focused on the research and development of

Via Spotlight Growth

ADAP Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Adaptimmune Therapeutics plc Is Fair to Shareholders

March 06, 2023

From Halper Sadeh LLC

Via Business Wire

Adaptimmune Reports Fourth-Quarter and Full Year Financial Results and Business Update

March 06, 2023

BLA submission initiated for afami-cel, with aim to complete in mid-2023; afami-cel has the potential to be the first marketed...

Via Newsfile

Adaptimmune and TCR2 Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors

March 06, 2023

Compelling clinical data with clear paths to products and multiple near‐term value-creating catalystsComplementary technology platforms designed to treat solid tumors...

Via Newsfile

Adaptimmune to Report Q4 and Full Year 2022 Financial and Business Updates on Monday, March 6, 2023

February 22, 2023

Philadelphia, Pennsylvania and Oxfordshire, United Kingdom--(Newsfile Corp. - February 22, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in...

Via Newsfile

Adaptimmune Announces Changes to Board of Directors

February 16, 2023

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - February 16, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in...

Via Newsfile

Publication of Data from Adaptimmune's Completed Phase 1 Trial with Afami-cel in Nature Medicine Demonstrating an Acceptable Safety Profile and Encouraging Responses in Synovial Sarcoma

January 09, 2023

-The response rate was 44% in patients with late-stage, metastatic synovial sarcoma after a single dose of afami-cel --...

Via Newsfile

Adaptimmune Announces Initiation of Biologics License Application (BLA) Submission for Afami-cel, Its First-Gen Engineered TCR T-cell Therapy targeting MAGE-A4, For the Treatment of Synovial Sarcoma

December 23, 2022

- Afami-cel has the potential to be the first approved engineered TCR T-cell therapy for a solid tumor - -Synovial...

Via Newsfile

Data from Cohort 1 of SPEARHEAD-1 Trial at CTOS Continue to Support BLA Submission for Afami-cel in Synovial Sarcoma - Response Rate and Durability Remain Consistent

November 18, 2022

- Data indicate continued clinical responses with an acceptable safety profile in heavily pre-treated patients with late-stage synovial sarcoma after...

Via Newsfile

Adaptimmune Reports Third-Quarter Financial Results and Business Update

November 08, 2022

Adaptimmune will focus on programs in MAGE-A4 and PRAME, two of the most validated T-Cell targets in solid tumors Adaptimmune will...

Via Newsfile

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Adaptimmune Therapeutics plc - American Depositary Shares (NQ:ADAP)

Press Releases about Adaptimmune Therapeutics plc - American Depositary Shares

Starting at $3.75/week.

Subscribe Today